The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AVANIR Pharmaceuticals's share price is €14.37.
AVANIR Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €0.53. Hence, AVANIR Pharmaceuticals's PS Ratio for today is 27.22.
The historical rank and industry rank for AVANIR Pharmaceuticals's PS Ratio or its related term are showing as below:
FRA:AV2B'
s PS Ratio Range Over the Past 10 Years
Min: 2.23 Med: 19.41 Max: 119.75
Current: 23.89
During the past 13 years, AVANIR Pharmaceuticals's highest PS Ratio was 119.75. The lowest was 2.23. And the median was 19.41.
FRA:AV2B's PS Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.18
vs FRA:AV2B: 23.89
AVANIR Pharmaceuticals revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of AVANIR Pharmaceuticals was 31.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 99.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 124.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.80% per year.
During the past 13 years, AVANIR Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 160.40% per year. The lowest was 0.00% per year. And the median was -9.10% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVANIR Pharmaceuticals's PS Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVANIR Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where AVANIR Pharmaceuticals's PS Ratio falls into.
AVANIR Pharmaceuticals PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
AVANIR Pharmaceuticals's Share Price of today is €14.37. AVANIR Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
AVANIR Pharmaceuticals (FRA:AV2B) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
AVANIR Pharmaceuticals PS Ratio Related Terms
Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
AVANIR Pharmaceuticals (FRA:AV2B) Business Description
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AV2B has been successfully added to your 